India · Delayed Price · Currency is INR Orchid Pharma Statistics
Total Valuation
Orchid Pharma has a market cap or net worth of INR 52.02 billion. The enterprise value is 54.81 billion.
| Market Cap | 52.02B |
| Enterprise Value | 54.81B |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 50.72M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.40% |
| Owned by Insiders (%) | 19.47% |
| Owned by Institutions (%) | 61.77% |
| Float | 40.84M |
Valuation Ratios
The trailing PE ratio is 173.27.
| PE Ratio | 173.27 |
| Forward PE | n/a |
| PS Ratio | 5.99 |
| PB Ratio | 3.96 |
| P/TBV Ratio | 4.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 40.63 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 182.75 |
| EV / Sales | 6.32 |
| EV / EBITDA | 90.50 |
| EV / EBIT | 227.29 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 5.97 |
| Debt / FCF | -1.37 |
| Interest Coverage | 1.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 1.45% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 7.29M |
| Profits Per Employee | 252,041 |
| Employee Count | 1,169 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.25% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +35.25% |
| 50-Day Moving Average | 1,002.92 |
| 200-Day Moving Average | 801.16 |
| Relative Strength Index (RSI) | 49.58 |
| Average Volume (20 Days) | 8,287 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orchid Pharma had revenue of INR 8.52 billion and earned 294.64 million in profits. Earnings per share was 5.81.
| Revenue | 8.52B |
| Gross Profit | 3.06B |
| Operating Income | 249.04M |
| Pretax Income | 293.44M |
| Net Income | 294.64M |
| EBITDA | 607.09M |
| EBIT | 249.04M |
| Earnings Per Share (EPS) | 5.81 |
Balance Sheet
The company has 832.11 million in cash and 3.63 billion in debt, with a net cash position of -2.79 billion.
| Cash & Cash Equivalents | 832.11M |
| Total Debt | 3.63B |
| Net Cash | -2.79B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.88B |
| Book Value Per Share | 253.98 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 1.26 billion and capital expenditures -3.90 billion, giving a free cash flow of -2.64 billion.
| Operating Cash Flow | 1.26B |
| Capital Expenditures | -3.90B |
| Depreciation & Amortization | 358.05M |
| Net Borrowing | 1.47B |
| Free Cash Flow | -2.64B |
| FCF Per Share | n/a |
Margins
Gross margin is 35.85%, with operating and profit margins of 2.92% and 3.46%.
| Gross Margin | 35.85% |
| Operating Margin | 2.92% |
| Pretax Margin | 3.44% |
| Profit Margin | 3.46% |
| EBITDA Margin | 7.12% |
| EBIT Margin | 2.92% |
| FCF Margin | n/a |
Dividends & Yields
Orchid Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.08% |
| Shareholder Yield | 0.08% |
| Earnings Yield | 0.58% |
| FCF Yield | -5.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Orchid Pharma is 968.67, which is -5.57% lower than the current price. The consensus rating is "Buy".
| Price Target | 968.67 |
| Price Target Difference | -5.57% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |